within Pharmacolibrary.Drugs.ATC.J;

model J05AE04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 6.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 20.400000000000002,            
    Vdp             = 0.0022,
    k12             = 1.47,
    k21             = 1.47
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AE04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nelfinavir is an orally administered HIV-1 protease inhibitor that was previously used in combination antiretroviral therapy for the treatment of HIV infection. It is less commonly used today due to the availability of newer agents with improved safety and efficacy profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration in fasting state.</p><h4>References</h4><ol><li><p>Lennernäs, H (2003). Clinical pharmacokinetics of atorvastatin. <i>Clinical pharmacokinetics</i> 42(13) 1141–1160. DOI:<a href=\"https://doi.org/10.2165/00003088-200342130-00005\">10.2165/00003088-200342130-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14531725/\">https://pubmed.ncbi.nlm.nih.gov/14531725</a></p></li><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=\"https://doi.org/10.2165/00003088-200342090-00003\">10.2165/00003088-200342090-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12882588/\">https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Goldsmith, DR, &amp; Perry, CM (2003). Atazanavir. <i>Drugs</i> 63(16) 1679–1695. DOI:<a href=\"https://doi.org/10.2165/00003495-200363160-00003\">10.2165/00003495-200363160-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12904086/\">https://pubmed.ncbi.nlm.nih.gov/12904086</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AE04;
